NCT01740908

Stem Cell Quantification In Peripheral Blood After Hyperbaric Oxygen Therapy Treatments

Pilot Study for the Detection of Stem/Progenitor Cell Up-regulation Using Aldagen BRIGHT Technology in Peripheral Blood After Hyperbaric Oxygen Therapy (HBOT) Treatment

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 8 (estimated)
• Sponsor: Restorix Research Institute, LLLP · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is an observational research study whose purposes are to see the effects of repeated hyperbaric oxygen therapy treatments on the levels of stem/progenitor cells in peripheral circulating blood following five days of treatment, 90 minutes per day at 2.0 atmospheres absolute in 100% USP Grade Oxygen. Hyperbaric oxygen has a greater oxygen concentration than air at sea level. In this research, the concentration of oxygen will be twice the level of oxygen at sea level.

Conditions

• Changes in Peripheral Blood Population Numbers and Type.

Interventions

Type	Name	Description
OTHER	Hyperbaric Oxygen Treatment	Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle. All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days.

Timeline

• Start date: 2012-12-01
• Primary completion: 2012-12-01
• Completion: 2013-01-01
• First posted: 2012-12-04
• Last updated: 2012-12-04

Locations

1 site across 1 country: United States